Skip to content
Imfinzi(durvalumab)
Imfinzi (durvalumab) is an antibody pharmaceutical. Durvalumab was first approved as Imfinzi on 2017-05-01. It is used to treat transitional cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against programmed cell death 1 ligand 1.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Imfinzi
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Durvalumab
Tradename
Proper name
Company
Number
Date
Products
ImfinzidurvalumabAstraZeneca UK LtdN-761069 RX2017-05-01
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
imfinziBiologic Licensing Application2021-02-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
transitional cell carcinoma—D002295—
Agency Specific
FDA
EMA
Expiration
Code
durvalumab, Imfinzi, AstraZeneca UK Ltd
2029-10-21Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF03: Durvalumab
HCPCS
Code
Description
J9173
Injection, durvalumab, 10 mg
Clinical
Clinical Trials
620 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228933903113146
NeoplasmsD009369C803826—1—52
Neoplasm metastasisD009362EFO_00097081——1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.9012343—244
Breast neoplasmsD001943EFO_0003869C5022291—142
Squamous cell carcinoma of head and neckD00007719517203——33
Liver neoplasmsD008113EFO_1001513C22.08205—231
Small cell lung carcinomaD0557526164—328
Ovarian neoplasmsD010051EFO_0003893C5615181——26
Urinary bladder neoplasmsD001749C679182——25
Renal cell carcinomaD0022927122——18
Biliary tract neoplasmsD001661C24.93111——13
Urologic neoplasmsD014571C64-C68382——11
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151791726———34
Pancreatic neoplasmsD010190EFO_0003860C251723———32
Triple negative breast neoplasmsD0647261013———20
Head and neck neoplasmsD0062581111———14
MelanomaD00854596——113
Stomach neoplasmsD013274EFO_0003897C16611———13
CholangiocarcinomaD018281C22.1211———13
Prostatic neoplasmsD011471C6149———11
Uterine cervical neoplasmsD00258377———11
Esophageal neoplasmsD004938C1549———10
Show 71 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728D47.42————2
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Myelomonocytic leukemia chronicD015477C93.11————1
AnemiaD000740EFO_0004272D64.91————1
Hodgkin diseaseD006689C811————1
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.21————1
Myeloid leukemia chronic-phaseD0154661————1
ThrombocytosisD013922D75.831————1
PolycythemiaD011086EFO_0005804D75.11————1
Show 12 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDURVALUMAB
INNdurvalumab
Description
Durvalumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)DURVALUMAB
Structure (InChI/SMILES or Protein Sequence)
>5X8M:B|durvalumab heavy chain EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLY LQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH >5X8M:C|durvalumab light chain EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5X8M, 5XJ4
CAS-ID1428935-60-7
RxCUI1919503
ChEMBL IDCHEMBL3301587
ChEBI ID—
PubChem CID—
DrugBankDB11714
UNII ID28X28X9OKV (ChemIDplus, GSRS)
Target
Agency Approved
CD274
CD274
Organism
Homo sapiens
Gene name
CD274
Gene synonyms
B7H1, PDCD1L1, PDCD1LG1, PDL1
NCBI Gene ID
29126
Protein name
programmed cell death 1 ligand 1
Protein synonyms
B7 homolog 1, B7-H1, CD274, CD274 antigen, PDCD1 ligand 1
Uniprot ID
Q9NZQ7
Mouse ortholog
Cd274 (60533)
programmed cell death 1 ligand 1 (Q9EP73)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Imfinzi - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 13,280 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
71,483 adverse events reported
View more details